Cargando…

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma

PURPOSE: Based on improvements of progression-free survival (PFS), new agents for metastatic renal cell carcinoma (mRCC) have been approved. It is assumed that one of the benefits is a delay in health-related quality of life (HRQoL) deterioration as a result of a delay in progression of disease. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Groot, S., Redekop, W. K., Versteegh, M. M., Sleijfer, S., Oosterwijk, E., Kiemeney, L. A. L. M., Uyl-de Groot, C. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770482/ https://www.ncbi.nlm.nih.gov/pubmed/28917029 http://dx.doi.org/10.1007/s11136-017-1704-4

Ejemplares similares

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry
por: De Groot, S., et al.
Publicado: (2016)

Health-related quality of life of multiple sclerosis patients: a European multi-country study
por: Visser, Laurenske A., et al.
Publicado: (2021)

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
por: Zaim, Remziye, et al.
Publicado: (2023)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

Economic evaluations of big data analytics for clinical decision-making: a scoping review
por: Bakker, Lytske, et al.
Publicado: (2020)

How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care
por: Bakker, Lytske, et al.
Publicado: (2021)

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
por: Bakker, LJ, et al.
Publicado: (2023)

Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers
por: de Groot, Saskia, et al.
Publicado: (2015)

Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach
por: Clarijs, Marloes E., et al.
Publicado: (2021)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
por: Ansaripour, Amir, et al.
Publicado: (2018)

Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model
por: Franken, Mira D., et al.
Publicado: (2020)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis
por: Visser, Laurenske A., et al.
Publicado: (2021)

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
por: Uyl-de Groot, Carin A., et al.
Publicado: (2020)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation
por: Mulder, E.E.A.P., et al.
Publicado: (2021)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Cigarette smoking, von Hippel–Lindau gene mutations and sporadic renal cell carcinoma
por: van Dijk, B A C, et al.
Publicado: (2006)

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks
por: van der Gronde, Toon, et al.
Publicado: (2017)

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma
por: Cella, David, et al.
Publicado: (2014)

Cohort profile – the Renal cell cancer: Lifestyle, prognosis and quality of life (ReLife) study in the Netherlands
por: Maurits, Jake S F, et al.
Publicado: (2023)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence
por: Bosch, Dianne, et al.
Publicado: (2023)

Systematic reviews as a “lens of evidence”: Determinants of cost‐effectiveness of breast cancer screening
por: Mandrik, Olena, et al.
Publicado: (2019)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Determinants of renal cell carcinoma invasion and metastatic competence
por: Kim, Kangsan, et al.
Publicado: (2021)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Onderdiagnostiek bij kanker door de COVID-19-crisis naar diagnose, leeftijd en provincie: Een cruciale rol voor eerstelijnszorgverleners
por: Uyl-de Groot, Carin A., et al.
Publicado: (2020)

The cost-effectiveness of (18)FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy
por: van Hooren, Addy C. G., et al.
Publicado: (2008)

Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
por: Aragon-Ching, Jeanny B.
Publicado: (2021)

Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma
por: Oosterwijk-Wakka, Jeannette C., et al.
Publicado: (2013)

Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome
por: van Beurden-Tan, Chrissy H. Y., et al.
Publicado: (2022)

Quality of life among people living with HIV in England and the Netherlands: a population-based study
por: Popping, Stephanie, et al.
Publicado: (2021)

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
por: Holleman, Marscha S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h8n0qii7o8jjdbks07hetm38gu